© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#bictegravir

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.

Biktarvy

Integrase Inhibitors May Be Tied to Weight Gain

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
The opening session of CROI 2018 in Boston.

The Best of CROI 2018

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Gilead Releases HIV Regimen Biktarvy, ViiV Sues for Patent Infringement

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

Gilead’s New Bictegravir-Based HIV Combo Pill Performs Well

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

“Holy Grail” HIV Regimen Awaits FDA OK

The single-tablet HIV treatment regimen includes the experimental integrase inhibitor bictegravir and the contents of Descovy.
French AIDS ambassador Michèle Boccoz, executive director of UNAIDS Michel Sidibé, mayor of Paris Anne Hidalgo and Christine Kafando, a community health worker from Burkina Faso, speak at a press conference on the new 90-90-90 UNAIDS report.

International HIV Conference Reveals Exciting Progress in Global HIV Fight

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
Joel Gallant, MD, at IAS 2017

New Integrase Inhibitor Is Effective for First-Time Treatment

Gilead Sciences’ bictegravir-containing combo also has fewer side effects.

Gilead Files For FDA Approval of Integrase Inhibitor–Based HIV Regimen

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Bictegravir Shows Promise as Part of Future Single-Tablet HIV Regimen

The investigational integrase inhibitor bictegravir appears to have a resistance profile superior to currently available drugs in its class.
Advertisement